143 related articles for article (PubMed ID: 30379408)
1. Correlation between pre-treatment serum carcinoembryonic antigen levels and genotypes in a large population of Chinese people with advanced lung adenocarcinoma.
Liu J; Zhao YQ; Han X; Hu XF; Wu HB; Chen LJ; Song YP
Intern Med J; 2019 May; 49(5):634-643. PubMed ID: 30379408
[TBL] [Abstract][Full Text] [Related]
2. Serum carcinoembryonic antigen levels before initial treatment are associated with EGFR mutations and EML4- ALK fusion gene in lung adenocarcinoma patients.
Wang WT; Li Y; Ma J; Chen XB; Qin JJ
Asian Pac J Cancer Prev; 2014; 15(9):3927-32. PubMed ID: 24935562
[TBL] [Abstract][Full Text] [Related]
3. Correlation between serum CEA levels and EGFR mutations in Chinese nonsmokers with lung adenocarcinoma.
Jin B; Dong Y; Wang HM; Huang JS; Han BH
Acta Pharmacol Sin; 2014 Mar; 35(3):373-80. PubMed ID: 24487967
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma.
Feng LX; Wang J; Yu Z; Song SA; Zhai WX; Dong SH; Yu HS; Zhang Y
Clin Transl Oncol; 2019 Aug; 21(8):1005-1013. PubMed ID: 30637712
[TBL] [Abstract][Full Text] [Related]
5. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis.
Wang S; Ma P; Ma G; Lv Z; Wu F; Guo M; Li Y; Tan Q; Song S; Zhou E; Geng W; Duan Y; Li Y; Jin Y
Eur J Cancer; 2020 Jan; 124():1-14. PubMed ID: 31707279
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.
Gao Y; Song P; Li H; Jia H; Zhang B
BMC Cancer; 2017 Jul; 17(1):484. PubMed ID: 28705152
[TBL] [Abstract][Full Text] [Related]
7. [Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma].
Chen H; Yang X; Liu H; Ma K; Zhong J; Dong Z; Zhuo M; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):589-597. PubMed ID: 28935011
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum tumor markers and Anaplastic Lymphoma Kinase mutations in stage IV lung adenocarcinoma in Hubei province, Central China.
Tan Q; Huang Q; Ma G; Lv Z; Mei P; Mao K; Wu F; Jin Y
J Clin Lab Anal; 2020 Jan; 34(1):e23027. PubMed ID: 31489711
[TBL] [Abstract][Full Text] [Related]
9. Monitoring of carcinoembryonic antigen levels is predictive of EGFR mutations and efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Zhang Y; Jin B; Shao M; Dong Y; Lou Y; Huang A; Han B
Tumour Biol; 2014 May; 35(5):4921-8. PubMed ID: 24459065
[TBL] [Abstract][Full Text] [Related]
10. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
11. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.
Shoji F; Yoshino I; Yano T; Kometani T; Ohba T; Kouso H; Takenaka T; Miura N; Okazaki H; Maehara Y
Cancer; 2007 Dec; 110(12):2793-8. PubMed ID: 17941001
[TBL] [Abstract][Full Text] [Related]
12. Associations between epidermal growth factor receptor gene mutation and serum tumor markers in advanced lung adenocarcinomas: a retrospective study.
Pan YQ; Shi WW; Xu DP; Xu HH; Zhou MY; Yan WH
Chin Med Sci J; 2014 Sep; 29(3):156-61. PubMed ID: 25264883
[TBL] [Abstract][Full Text] [Related]
13. Value of ¹⁸F-FDG uptake on PET/CT and CEA level to predict epidermal growth factor receptor mutations in pulmonary adenocarcinoma.
Ko KH; Hsu HH; Huang TW; Gao HW; Shen DH; Chang WC; Hsu YC; Chang TH; Chu CM; Ho CL; Chang H
Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1889-97. PubMed ID: 24852187
[TBL] [Abstract][Full Text] [Related]
14. Correlation between efficacy of the EGFR tyrosine kinase inhibitor and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Clin Lab; 2014; 60(9):1439-47. PubMed ID: 25291939
[TBL] [Abstract][Full Text] [Related]
15. Prognostic stratification of pathological node-negative lung adenocarcinoma by carcinoembryonic antigen level.
Batmunkh K; Cho S; Yum S; Kim K; Jheon S
Interact Cardiovasc Thorac Surg; 2020 Jun; 30(6):820-826. PubMed ID: 32221597
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of pleural fluid carcinoembryonic antigen on therapeutic strategy and efficacy in lung adenocarcinoma patients with malignant pleural effusion.
Lee J; Lee DH; Park JE; Lee YH; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Korean J Intern Med; 2024 Mar; 39(2):318-326. PubMed ID: 38351680
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of serum CYFRA 21-1 in patients with advanced lung adenocarcinoma: a retrospective study.
Ono A; Takahashi T; Mori K; Akamatsu H; Shukuya T; Taira T; Kenmotsu H; Naito T; Murakami H; Nakajima T; Endo M; Yamamoto N
BMC Cancer; 2013 Jul; 13():354. PubMed ID: 23879483
[TBL] [Abstract][Full Text] [Related]
18. Association between serum biomarkers CEA and LDH and response in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
de Jong C; Deneer VHM; Kelder JC; Ruven H; Egberts TCG; Herder GJM
Thorac Cancer; 2020 Jul; 11(7):1790-1800. PubMed ID: 32383328
[TBL] [Abstract][Full Text] [Related]
19. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
[TBL] [Abstract][Full Text] [Related]
20. Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers.
Yang ZM; Ding XP; Pen L; Mei L; Liu T
Asian Pac J Cancer Prev; 2014; 15(8):3451-5. PubMed ID: 24870738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]